Effects of Niacin on Glucose Control in Patients with Dyslipidemia
- BETA-SITOSTEROL: AN ANTI-INFLAMMATORY AND ANTI-CHOLESTEROL PLANT. Haas, Robert // Life Extension;Mar2010, Vol. 16 Issue 3, Special section p5
The article discusses research into the use of beta-sitosterol for the treatment of inflammation and high cholesterol. The natural cholesterol-lowering compounds include policosanol and niacin. The author notes that natural compounds can be an effective alternative to the use of high-dose statin...
- Niacin Beats Ezetimibe Head to Head. // Internal Medicine Alert;12/15/2009 Pharmacology Watch, p1
The article presents a study which examines the impact of statin and niacin on the level of high-density lipoprotein-cholesterol (HDL-C).
- Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Goldie, Christina; Taylor, Allen J.; Nguyen, Peter; McCoy, Cody; Xue-Qiao Zhao; Preiss, David; Zhao, Xue-Qiao // Heart;Feb2016, Vol. 102 Issue 3, p198
Objective:Previous studies have suggested that niacin treatment raises glucose levels in patients with diabetes and may increase the risk of developing diabetes. We undertook a meta-analysis of published and unpublished data from randomised trials to confirm whether an association...
- Diabetic dyslipidemia: A practical guide to therapy. Tovar, John M.; Bazaldua, Oralia V.; Loffredo, Alexandra // Journal of Family Practice;Jun2008, Vol. 57 Issue 6, p377
The article outlines the research conducted on the medications used in effectively treating diabetic dyslipidemia patients in the U.S. Figures reveal that among 7000 patients with diabetes, 72% were treated with hyperglycemia and 64% for hypertension, but only 28% were treated for dyslipidemia....
- Statins and secondary prevention of coronary heart disease. Ahmed, Mehboub; Griffiths, Peter // British Journal of Community Nursing;April2004, Vol. 9 Issue 4, p160
Assesses the effectiveness of lipid-lowering treatments, such as statins, in the secondary prevention of myocardial infarction (MI). Trials demonstrating that statins had a clear and consistent effect in significantly reducing the risk of MI; Approximate decline in MI produced from three trials.
- Retrospective analysis demonstrates that switching statins hinders treatment compliance, persistence. // Formulary;Jan2006, Vol. 41 Issue 1, p36
The article reports on the results of a retrospective analysis of patients who have switched statins. It is suggested that even if switching statins is a necessary tool of drug therapy for lipid management, it should be done with carefulness. The difference in persistence between switchers and...
- Add-on statin in postcode lottery row. // Pulse;9/22/2003, Vol. 63 Issue 38, p4
Reports on the availability of add-on statin ezetimibe in Scotland. Details of an Executive decision to recommend the use of the drug in patient with high cholesterol levels; Issues related to statin prescribing.
- BETTER THAN STATINS. // Nutrition Action Health Letter;May2002, Vol. 29 Issue 4, p6
Reports on the results of a study on the use of statin drugs and a healthy diet to lower low-density lipoprotein cholesterol.
- Statins and cardiac benefits. // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p19
Examines the drug properties of statins beyond diminishing cholesterol levels. Differences in the reactions of the drugs usage in terms of vascular disease; Reproduction of platelet activity and aggregation; Increase of bone formation and mineral density.